GLT1D1 Inhibitors
Chemical inhibitors of GLT1D1 function through various mechanisms to impede the signaling pathways this protein is involved in. LY294002 and Wortmannin are two inhibitors that target Phosphatidylinositol 3-kinase (PI3K), a pivotal enzyme upstream of Akt signaling, which is crucial for GLT1D1 activity. By inhibiting PI3K, these chemicals lead to reduced phosphorylation and activity of Akt, subsequently leading to a decrease in GLT1D1 function. Similarly, Akt inhibitor VIII directly suppresses Akt, further preventing the activation of GLT1D1 through this pathway. Rapamycin and AZD8055, meanwhile, focus on inhibiting the mammalian target of rapamycin (mTOR) pathway, with Rapamycin forming a complex that inhibits mTOR Complex 1 (mTORC1) and AZD8055 targeting both mTORC1 and mTORC2 complexes. This inhibition cuts back on the signaling necessary for GLT1D1's role downstream. PF-4708671 contributes to this reduction in function by selectively inhibiting p70S6 Kinase (S6K1), a kinase that operates within the PI3K/Akt pathway and is relevant to GLT1D1's function.
In parallel, a series of inhibitors act on the Mitogen-Activated Protein Kinase (MAPK) pathways. U0126, PD98059, and SL327 are specific inhibitors of MEK1/2, which is upstream of the extracellular signal-regulated kinases ERK1/2, both central to the MAPK/ERK pathway. Inhibition of MEK1/2 by these chemicals prevents the activation of ERK1/2, thereby reducing the activity of downstream proteins such as GLT1D1. LY3214996 specifically inhibits ERK1 and ERK2, leading to a direct reduction in GLT1D1 activity. SB203580 and SP600125 are selective inhibitors of p38 MAPK and c-Jun N-terminal kinase (JNK), respectively. These kinases are components of the MAPK pathway, and their inhibition by these chemicals suppresses the downstream signaling that GLT1D1 is a part of. Collectively, these inhibitors work to decrease the functional activity of GLT1D1 by targeting and impeding the activity of key proteins in its signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $204.00 $265.00 | 29 | |
This inhibitor directly targets Akt, also known as protein kinase B, which is involved in the same pathway as GLT1D1. By inhibiting Akt, the phosphorylation and activation of downstream proteins that require Akt for proper functioning, such as GLT1D1, are also inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in the PI3K/Akt pathway, by binding to FKBP12 and the resulting complex binds to mTOR Complex 1 (mTORC1). Since GLT1D1 operates within this pathway, inhibiting mTOR can lead to a decrease in the functional activity of GLT1D1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key kinases in the MAPK/ERK pathway, which is another pathway where GLT1D1 is involved. Inhibition of MEK1/2 by U0126 prevents the activation of ERK1/2, thus potentially inhibiting the functional activity of GLT1D1 downstream of ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK, which is part of the MAPK pathway, where GLT1D1 plays a role. Inhibition of p38 MAPK can suppress the downstream signaling required for GLT1D1 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, similar to LY294002, and by inhibiting PI3K it reduces Akt activity. As Akt signaling is necessary for GLT1D1, wortmannin's effect can inhibit the functional activity of GLT1D1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which is upstream of ERK in the MAPK pathway. Through this inhibition, the functional activation of GLT1D1, which is active in this pathway, is also inhibited. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway, which interconnects with the signaling pathways of GLT1D1. By inhibiting JNK, the chemical can lead to reduced function of GLT1D1. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $260.00 | ||
LY3214996 specifically inhibits ERK1 and ERK2, which are downstream in the MAPK pathway. As GLT1D1 is associated with this pathway, inhibiting ERK1/2 could lead to a reduction in GLT1D1 activity. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 is a selective inhibitor of the p70S6 Kinase (S6K1), a protein kinase involved in the PI3K/Akt pathway. Inhibition of S6K1 can disrupt the function of downstream proteins in this pathway, including GLT1D1. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an inhibitor of both mTORC1 and mTORC2 complexes, which are integral to the PI3K/Akt pathway. By inhibiting these complexes, AZD8055 can suppress the pathway's function and thus inhibit GLT1D1's activity. | ||||||